Sujal Shah

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Sujal Shah
Non-Executive Director / Opthea

Mr Shah brings two decades of experience as a biopharmaceutical executive and strategic advisor to the Opthea Board. Most recently, Mr Shah served as President and Chief Executive Officer at CymaBay Therapeutics, a clinicalstage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Mr Shah joined CymaBay as Chief Financial Officer, taking the company public in 2013. Prior to CymaBay, Mr Shah was a healthcare investment bankerfor Citigroup Inc. as well as Credit Suisse, where he wasresponsible for managing client relationships and executing strategic and financing related transactions for clients on life sciences. Mr Shah currently serves as Chairman of the Board of Tvardi Therapeutics and as a Director on the Board of Stratus Therapeutics.

Lists and Charts

Roles

2024
Non-Executive Director
Opthea
Year started and most recent title

Total Shareholder Return as at 02/12/24

Rank Company 1 Yr 5 Yr
289th Insurance Australia Group">Insurance Australia Group 49.2% 4.54%
290th G8 Education">G8 Education 49.04% -3.86%
291st Opthea">Opthea 48.89% -21.2%
292nd Everest Metals Corporation">Everest Metals Corporation 48.84% 90.28%
293rd Axiom Properties">Axiom Properties 48.78% 16.85%
View Full List
1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

      Person Activity

      		 NEW ROLE: Non-Executive Director, Opthea 07 Aug 2024

    Related Information

    Access to our data for Sujal Shah is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Sujal Shah is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X